Midwest CRA - Myelofibrosis
Apply NowCompany: Catalyst Clinical Research
Location: Chicago, IL 60601
Description:
Job Description
Indication is Phase II Oncology(bone marrow cancers), specifically Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) Need 2 Blinded US CRAs - 10 sites in total, so each CRA will cover approx. 5 sites - still assessing where sites may be Start Date for US CRAs is Mid/End March 1 East- allocation approx. 80% 1 West- allocation approx. 80% Need 1 Blinded CRA for Central Canada(for ease of travel to Eastern or Western Canada) Allocation approx. 40% sites total for Canada - 1 Eastern Canada and 1 Western Canada Start for Canadian CRA is early April Also need 1 Unblinded CRA who is centrally located and can travel to all sites in the 10 US and the 2 Canadian sites). Start: April/May 2015 (only training in the beginning), action for this CRA starts when initiations are there. So these hours will be made in less months than 21. Allocation roughly 50-60% Study duration 22 Months Waiting on EDC system information
Experience Required
Indication is Phase II Oncology(bone marrow cancers), specifically Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) Need 2 Blinded US CRAs - 10 sites in total, so each CRA will cover approx. 5 sites - still assessing where sites may be Start Date for US CRAs is Mid/End March 1 East- allocation approx. 80% 1 West- allocation approx. 80% Need 1 Blinded CRA for Central Canada(for ease of travel to Eastern or Western Canada) Allocation approx. 40% sites total for Canada - 1 Eastern Canada and 1 Western Canada Start for Canadian CRA is early April Also need 1 Unblinded CRA who is centrally located and can travel to all sites in the 10 US and the 2 Canadian sites). Start: April/May 2015 (only training in the beginning), action for this CRA starts when initiations are there. So these hours will be made in less months than 21. Allocation roughly 50-60% Study duration 22 Months Waiting on EDC system information
Indication is Phase II Oncology(bone marrow cancers), specifically Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) Need 2 Blinded US CRAs - 10 sites in total, so each CRA will cover approx. 5 sites - still assessing where sites may be Start Date for US CRAs is Mid/End March 1 East- allocation approx. 80% 1 West- allocation approx. 80% Need 1 Blinded CRA for Central Canada(for ease of travel to Eastern or Western Canada) Allocation approx. 40% sites total for Canada - 1 Eastern Canada and 1 Western Canada Start for Canadian CRA is early April Also need 1 Unblinded CRA who is centrally located and can travel to all sites in the 10 US and the 2 Canadian sites). Start: April/May 2015 (only training in the beginning), action for this CRA starts when initiations are there. So these hours will be made in less months than 21. Allocation roughly 50-60% Study duration 22 Months Waiting on EDC system information
Experience Required
Indication is Phase II Oncology(bone marrow cancers), specifically Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) Need 2 Blinded US CRAs - 10 sites in total, so each CRA will cover approx. 5 sites - still assessing where sites may be Start Date for US CRAs is Mid/End March 1 East- allocation approx. 80% 1 West- allocation approx. 80% Need 1 Blinded CRA for Central Canada(for ease of travel to Eastern or Western Canada) Allocation approx. 40% sites total for Canada - 1 Eastern Canada and 1 Western Canada Start for Canadian CRA is early April Also need 1 Unblinded CRA who is centrally located and can travel to all sites in the 10 US and the 2 Canadian sites). Start: April/May 2015 (only training in the beginning), action for this CRA starts when initiations are there. So these hours will be made in less months than 21. Allocation roughly 50-60% Study duration 22 Months Waiting on EDC system information